List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8361294/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	0.8	19
2	Monogenic forms of low-renin hypertension: clinical and molecular insights. Pediatric Nephrology, 2022, 37, 1495-1509.	0.9	15
3	Pre- versus post-operative untargeted plasma nuclear magnetic resonance spectroscopy metabolomics of pheochromocytoma and paraganglioma. Endocrine, 2022, 75, 254-265.	1.1	3
4	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension, 2022, 79, 187-195.	1.3	13
5	Predicting surgical outcome in posterior retroperitoneoscopic adrenalectomy with the aid of a preoperative nomogram. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 6507-6515.	1.3	2
6	The Hyperintense study: Assessing the effects of induced blood pressure increase and decrease on MRI markers of cerebral small vessel disease: Study rationale and protocol. European Stroke Journal, 2022, 7, 331-338.	2.7	2
7	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3689-e3698.	1.8	4
8	Adrenal Venous Sampling–Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1400-e1407.	1.8	25
9	Pregnancy and phaeochromocytoma/paraganglioma: clinical clues affecting diagnosis and outcome – a systematic review. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1264-1272.	1.1	14
10	Clinical presentation and longâ€ŧerm followâ€up of dopamine beta hydroxylase deficiency. Journal of Inherited Metabolic Disease, 2021, 44, 554-565.	1.7	13
11	Volumetric evaluation of CT images of adrenal glands in primary aldosteronism. Journal of Endocrinological Investigation, 2021, 44, 2359-2366.	1.8	4
12	Functional tests to guide management in an adult with loss of function of type-1 angiotensin II receptor. Pediatric Nephrology, 2021, 36, 2731-2737.	0.9	0
13	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4340-e4349.	1.8	18
14	Partial Adrenalectomy Carries a Considerable Risk of Incomplete Cure in Primary Aldosteronism. Journal of Urology, 2021, 206, 219-228.	0.2	4
15	Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: Asian Cohort Study. Endocrine Connections, 2021, 10, 834-844.	0.8	6
16	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	1.8	19
17	Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2042-2052.	1.8	65
18	Aldosterone-potassium ratio predicts primary aldosteronism subtype. Journal of Hypertension, 2020, 38, 1375-1383.	0.3	28

#	Article	IF	CITATIONS
19	Arterial Wall Inflammation and Increased Hematopoietic Activity in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1967-e1980.	1.8	27
20	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1919-1928.	0.3	151
21	A comparison of high-throughput plasma NMR protocols for comparative untargeted metabolomics. Metabolomics, 2020, 16, 64.	1.4	18
22	Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2719-2731.	1.8	8
23	N-of-1 Trials: Evidence-Based Clinical Care or Medical Research that Requires IRB Approval? A Practical Flowchart Based on an Ethical Framework. Healthcare (Switzerland), 2020, 8, 49.	1.0	18
24	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	1.8	17
25	Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference. Clinica Chimica Acta, 2020, 507, 98-103.	0.5	8
26	Low Quality of Reports on Blood Pressure in Patients Adrenalectomized for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2232-e2238.	1.8	4
27	Clinical biomarker innovation: when is it worthwhile?. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1712-1720.	1.4	2
28	Plasma levels of the cardiovascular protective endogenous nucleoside adenosine are reduced in patients with primary aldosteronism without affecting ischaemiaâ€reperfusion injury: A prospective caseâ€control study. European Journal of Clinical Investigation, 2019, 49, e13180.	1.7	4
29	Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. Hypertension, 2019, 74, 800-808.	1.3	97
30	A disease-specific Quality of Life questionnaire for primary aldosteronism. Endocrine Connections, 2019, 8, 389-397.	0.8	7
31	Adrenal venous sampling: cosyntropin stimulation or not?. European Journal of Endocrinology, 2019, 181, D15-D26.	1.9	31
32	Is the plasma aldosterone-to-renin ratio associated with blood pressure response to treatment in general practice?. Family Practice, 2019, 36, 154-161.	0.8	1
33	The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis. Cardiovascular Research, 2018, 114, 944-953.	1.8	48
34	Prevalence of primary aldosteronism in primary care: a cross-sectional study. British Journal of General Practice, 2018, 68, e114-e122.	0.7	41
35	Patient characteristics do not predict the individual response to antihypertensive medication: a cross-over trial. Family Practice, 2018, 35, 67-73.	0.8	4
36	Adrenal Vein Sampling Is the Preferred Method to Select Patients With Primary Aldosteronism for Adrenalectomy. Hypertension, 2018, 71, 10-14.	1.3	26

#	Article	IF	CITATIONS
37	5970Who to test for primary aldosteronism: development of a decision tool to select the right patients. European Heart Journal, 2018, 39, .	1.0	0
38	Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 16-24.	1.8	99
39	Patients with primary aldosteronism have lower circulating adenosine levels but similar susceptibility to ischemia-reperfusion compared to patients with essential hypertension. Atherosclerosis, 2018, 275, e119.	0.4	0
40	A pedunculated aldosteroneâ€producing adenoma drained by an extra vein causing puzzling results of adrenal vein sampling. Clinical Endocrinology, 2018, 89, 242-244.	1.2	3
41	Effect of Antihypertensive Medication on Cerebral Small Vessel Disease. Stroke, 2018, 49, 1531-1533.	1.0	65
42	Psychological Symptoms and Well-Being After Treatment for Primary Aldosteronism. Hormone and Metabolic Research, 2018, 50, 620-626.	0.7	3
43	A prediction model for primary aldosteronism when the salt loading test is inconclusive. Endocrine Connections, 2018, 7, 1308-1314.	0.8	3
44	Hydrochlorothiazide treatment increases the abundance of the NaCl cotransporter in urinary extracellular vesicles of essential hypertensive patients. American Journal of Physiology - Renal Physiology, 2017, 312, F1063-F1072.	1.3	15
45	Adrenal Vein Catecholamine Levels and Ratios: Reference Intervals Derived from Patients with Primary Aldosteronism. Hormone and Metabolic Research, 2017, 49, 418-423.	0.7	5
46	Plasma galectin-3 concentrations in patients with primary aldosteronism. Journal of Hypertension, 2017, 35, 1849-1856.	0.3	3
47	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	5.5	595
48	A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence. Journal of General Internal Medicine, 2017, 32, 921-930.	1.3	22
49	Congenital eyelid ptosis, decreased glomerular filtration, and orthostatic hypotension: Questions. Pediatric Nephrology, 2017, 32, 1169-1170.	0.9	2
50	Congenital eyelid ptosis, decreased glomerular filtration, and orthostatic hypotension: Answers. Pediatric Nephrology, 2017, 32, 1171-1174.	0.9	0
51	Health-Related Quality of Life and Mental Health in Primary Aldosteronism: A Systematic Review. Hormone and Metabolic Research, 2017, 49, 943-950.	0.7	28
52	Evaluating the learning curve for retroperitoneoscopic adrenalectomy in a high-volume center for laparoscopic adrenal surgery. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 2771-2775.	1.3	22
53	Effects of Treating Primary Aldosteronism on Renal Function. Journal of Clinical Hypertension, 2017, 19, 290-295.	1.0	28
54	Healthcare Technology Assessment of Medical Imaging Technology. Medical Radiology, 2017, , 171-183.	0.0	1

#	Article	IF	CITATIONS
55	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight, 2017, 2, .	2.3	187
56	Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 739-746.	5.5	208
57	Alternative splice variant of the thiazide-sensitive NaCl cotransporter: a novel player in renal salt handling. American Journal of Physiology - Renal Physiology, 2016, 310, F204-F216.	1.3	20
58	Eplerenone does not limit ischemia–reperfusion injury in human myocardial tissue. International Journal of Cardiology, 2016, 216, 110-113.	0.8	5
59	Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2826-2835.	1.8	250
60	Adrenal vein sampling versus CT scanning in primary aldosteronism – Authors' reply. Lancet Diabetes and Endocrinology,the, 2016, 4, 886-887.	5.5	0
61	Mass Spectrometry–Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. Clinical Chemistry, 2016, 62, 514-524.	1.5	123
62	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. Hypertension, 2016, 67, 139-145.	1.3	127
63	Central arteriovenous anastomosis and hypertension. Lancet, The, 2015, 386, 1821.	6.3	2
64	Network Meta-Analysis of Various Treatment Strategies in Resistant Hypertension. Value in Health, 2015, 18, A377.	0.1	3
65	Influence of the hospital environment and presence of the physician on the white-coat effect. Journal of Hypertension, 2015, 33, 2245-2249.	0.3	10
66	Should blood pressure be measured with the cuff on a bare arm?. Blood Pressure Monitoring, 2015, 20, 320-324.	0.4	6
67	Image Registration of Cone-Beam Computer Tomography and Preprocedural Computer Tomography Aids in Localization of Adrenal Veins and Decreasing Radiation Dose in Adrenal Vein Sampling. CardioVascular and Interventional Radiology, 2015, 38, 993-997.	0.9	16
68	Steroid Hormone Production in Patients with Aldosterone Producing Adenomas. Hormone and Metabolic Research, 2015, 47, 967-972.	0.7	14
69	Pharmacological treatment of aldosterone excess. , 2015, 154, 120-133.		31
70	Higher outdoor temperatures are progressively associated with lower blood pressure: a longitudinal study in 100,000 healthy individuals. Journal of the American Society of Hypertension, 2015, 9, 536-543.	2.3	25
71	An LC–MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 75-84.	1.2	129
72	The Effect of Eplerenone on Adenosine Formation in Humans In Vivo: A Double-Blinded Randomised Controlled Study. PLoS ONE, 2014, 9, e111248.	1.1	5

#	Article	IF	CITATIONS
73	Cardiac arrhythmias in hypokalemic periodic paralysis: Hypokalemia as only cause?. Muscle and Nerve, 2014, 50, 327-332.	1.0	14
74	Does wave reflection explain the increase in blood pressure during leg crossing?. Blood Pressure Monitoring, 2014, 19, 129-133.	0.4	2
75	Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism. Journal of Hypertension, 2014, 32, 115-126.	0.3	47
76	The cardioprotective effects of mineralocorticoid receptor antagonists. , 2014, 142, 72-87.		25
77	Adrenal Nodularity and Somatic Mutations in Primary Aldosteronism: One Node Is the Culprit?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1341-E1351.	1.8	94
78	Utility of LC-MS/MS based adrenal venous steroid profiling: Should cortisol remain the gold standard for selectivity and comparisons to aldosterone?. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	0.6	1
79	Cardiovascular complications during medication adjustment for the diagnosis of primary aldosteronism. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	0.6	0
80	Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nature Genetics, 2013, 45, 1055-1060.	9.4	446
81	Single versus duplicate blood samples in ACTH stimulated adrenal vein sampling. Clinica Chimica Acta, 2013, 423, 15-17.	0.5	4
82	Plasma Metanephrine for Assessing the Selectivity of Adrenal Venous Sampling. Hypertension, 2013, 62, 1152-1157.	1.3	65
83	Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. Journal of Hypertension, 2013, 31, 404-413.	0.3	23
84	A Novel Splice-Site Mutation in Angiotensin I-Converting Enzyme (ACE) Gene, c.3691+1G>A (IVS25+1G>A), Causes a Dramatic Increase in Circulating ACE through Deletion of the Transmembrane Anchor. PLoS ONE, 2013, 8, e59537.	1.1	22
85	Plasma metanephrine for assessing the selectivity of adrenal venous sampling. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, .	0.6	0
86	Hemoglobin Level Is Positively Associated With Blood Pressure in a Large Cohort of Healthy Individuals. Hypertension, 2012, 60, 936-941.	1.3	106
87	Aortic augmentation index and pulse wave velocity in response to head-up tilting. Journal of Hypertension, 2012, 30, 307-314.	0.3	28
88	Adrenal venous sampling crucial in primary aldosteronism?. Journal of Hypertension, 2012, 30, 433-435.	0.3	0
89	The efficacy of renal angioplasty in patients with renal artery stenosis and flash oedema or congestive heart failure: a systematic review. European Journal of Heart Failure, 2012, 14, 773-781.	2.9	23
90	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1606-1614.	1.8	310

#	Article	IF	CITATIONS
91	Leg vasoconstriction during head-up tilt in patients with autonomic failure is not abolished. Journal of Applied Physiology, 2011, 110, 416-422.	1.2	7
92	Neurocognitive Function in Dopamine-β-Hydroxylase Deficiency. Neuropsychopharmacology, 2011, 36, 1608-1619.	2.8	31
93	Is there still a place for adrenal venous sampling in the diagnostic localization of pheochromocytoma?. Endocrine, 2011, 40, 75-79.	1.1	6
94	Î ³ -Adducin Stimulates the Thiazide-sensitive NaCl Cotransporter. Journal of the American Society of Nephrology: JASN, 2011, 22, 508-517.	3.0	21
95	Angiotensin II contributes to the increased baseline leg vascular resistance in spinal cord-injured individuals. Journal of Hypertension, 2010, 28, 2094-2101.	0.3	38
96	The effect of crossing legs on blood pressure. Journal of Hypertension, 2010, 28, 1591-1592.	0.3	3
97	Sympathetic Nonadrenergic Transmission Contributes to Autonomic Dysreflexia in Spinal Cord–Injured Individuals. Hypertension, 2010, 55, 636-643.	1.3	16
98	Systematic Review: Diagnostic Procedures to Differentiate Unilateral From Bilateral Adrenal Abnormality in Primary Aldosteronism. Annals of Internal Medicine, 2009, 151, 329.	2.0	395
99	Which physiological mechanism is responsible for the increase in blood pressure during leg crossing?. Journal of Hypertension, 2008, 26, 433-437.	0.3	9
100	Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. Journal of Hypertension, 2008, 26, 928-937.	0.3	43
101	Reproducibility of the ambulatory arterial stiffness index in hypertensive patients. Journal of Hypertension, 2008, 26, 1993-2000.	0.3	20
102	Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype. Journal of Hypertension, 2008, 26, 706-713.	0.3	14
103	The effect of crossing legs on blood pressure. Blood Pressure Monitoring, 2007, 12, 189-193.	0.4	18
104	Heritability of blood pressure traits and the genetic contribution to blood pressure variance explained by four blood-pressure-related genes. Journal of Hypertension, 2007, 25, 565-570.	0.3	82
105	The position of the arm during blood pressure measurement in sitting position. Blood Pressure Monitoring, 2006, 11, 309-313.	0.4	28
106	Spotlight on Renin. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, 163-165.	1.0	20
107	Detection of Mutated Angiotensin I-Converting Enzyme by Serum/Plasma Analysis Using a Pair of Monoclonal Antibodies. Clinical Chemistry, 2005, 51, 1040-1043.	1.5	23
108	Renin, Prorenin and the Putative (Pro)renin Receptor. Hypertension, 2005, 46, 1069-1076.	1.3	215

#	Article	IF	CITATIONS
109	Rapid Screening Test for Primary Hyperaldosteronism: Ratio of Plasma Aldosterone to Renin Concentration Determined by Fully Automated Chemiluminescence Immunoassays. Clinical Chemistry, 2004, 50, 1650-1655.	1.5	98
110	DBH gene variants that cause low plasma dopamine � hydroxylase with or without a severe orthostatic syndrome. Journal of Medical Genetics, 2004, 41, e38-e38.	1.5	44
111	Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects. European Heart Journal, 2004, 25, 2143-2148.	1.0	49
112	Validation of a New Automated Renin Assay. Clinical Chemistry, 2004, 50, 2111-2116.	1.5	42
113	Which patients with hypertension and atherosclerotic renal artery stenosis benefit from immediate intervention?. Journal of Human Hypertension, 2004, 18, 91-96.	1.0	45
114	Congenital Dopamine-Î ² -Hydroxylase Deficiency in Humans. Annals of the New York Academy of Sciences, 2004, 1018, 520-523.	1.8	37
115	Smoking-dependent effects of the angiotensin-converting enzyme gene insertion/deletion polymorphism on blood pressure. Journal of Hypertension, 2004, 22, 313-319.	0.3	31
116	THE INFLUENCE OF GENETIC AND ENVIRONMENTAL FACTORS ON BLOOD PRESSURE VARIANCE IN A GENETICALLY ISOLATED POPULATION. Journal of Hypertension, 2004, 22, S215.	0.3	0
117	ANGIOTENSIN CONVERTING ENZYME INSERTION/DELETION POLYMORPHISM AND RISK OF HEART FAILURE IN HYPERTENSIVE SUBJECTS. Journal of Hypertension, 2004, 22, S213.	0.3	0
118	FREQUENCY AND HERITABILITY OF THE METABOLIC SYNDROME IN A GENETICALLY ISOLATED POPULATION. Journal of Hypertension, 2004, 22, S146.	0.3	0
119	Occam's razor; anaemia and orthostatic hypotension. Lancet, The, 2003, 362, 1282.	6.3	5
120	The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design. Journal of Nephrology, 2003, 16, 807-12.	0.9	71
121	Predictors for Clinical Success at One Year following Renal Artery Stent Placement. Journal of Endovascular Therapy, 2002, 9, 495-502.	0.8	14
122	The Renin-Angiotensin System and Vascular Disease in Diabetes. Seminars in Vascular Medicine, 2002, 2, 149-156.	2.1	14
123	Transendothelial transport of renin–angiotensin system components. Journal of Hypertension, 2002, 20, 2029-2037.	0.3	17
124	Functional effects of renal artery stent placement on treated and contralateral kidneys. Kidney International, 2002, 62, 574-579.	2.6	36
125	Predictors for Clinical Success at One Year Following Renal Artery Stent Placement. Journal of Endovascular Therapy, 2002, 9, 495-502.	0.8	7
126	Relationship between Natriuretic Peptide Concentrations in Plasma and Posture during Blood Sampling. Clinical Chemistry, 2001, 47, 963-965.	1.5	18

#	Article	IF	CITATIONS
127	Evaluation and treatment of renal artery stenosis: impact on blood pressure and renal function. Current Opinion in Nephrology and Hypertension, 2001, 10, 399-404.	1.0	3
128	Resistance to antihypertensive medication as predictor of renal artery stenosis: comparison of two drug regimens. Journal of Human Hypertension, 2001, 15, 669-676.	1.0	29
129	Increased Shedding of Angiotensin-converting Enzyme by a Mutation Identified in the Stalk Region. Journal of Biological Chemistry, 2001, 276, 5525-5532.	1.6	40
130	Point Mutation in the Stalk of Angiotensin-Converting Enzyme Causes a Dramatic Increase in Serum Angiotensin-Converting Enzyme But No Cardiovascular Disease. Circulation, 2001, 104, 1236-1240.	1.6	51
131	The Effect of Balloon Angioplasty on Hypertension in Atherosclerotic Renal-Artery Stenosis. New England Journal of Medicine, 2000, 342, 1007-1014.	13.9	839
132	Stent Placement for Renal Arterial Stenosis: Where Do We Stand? A Meta-analysis. Radiology, 2000, 216, 78-85.	3.6	379
133	Cystatin for estimation of glomerular filtration rate?. Lancet, The, 2000, 356, 1624-1625.	6.3	55
134	Improved Immunoradiometric Assay for Plasma Renin. Clinical Chemistry, 1999, 45, 847-854.	1.5	48
135	Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia, 1999, 42, 1006-1010.	2.9	140
136	Angiotensin I to angiotensin II conversion in the human forearm and leg. Effect of the angiotensin converting enzyme gene insertion/deletion polymorphism. Journal of Hypertension, 1999, 17, 1867-1872.	0.3	33
137	Probing epitopes on human prorenin during its proteolytic and non-proteolytic activation. BBA - Proteins and Proteomics, 1998, 1388, 386-396.	2.1	18
138	LOSARTAN, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST, REDUCES HEMATOCRITS IN KIDNEY TRANSPLANT RECIPIENTS WITH POSTTRANSPLANT ERYTHROCYTOSIS. Transplantation, 1997, 64, 780-782.	0.5	36
139	Angiotensin levels in the eye. Investigative Ophthalmology and Visual Science, 1994, 35, 1008-18.	3.3	154
140	Nonproteolytic "activation―of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. Journal of Biological Chemistry, 1992, 267, 22837-22842.	1.6	54
141	Nonproteolytic "activation" of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. Journal of Biological Chemistry, 1992, 267, 22837-42.	1.6	40
142	Identification and Quantification of Renin and Prorenin in the Bovine Eye. Endocrinology, 1990, 126, 1673-1682.	1.4	79
143	Renin, Prorenin, and Immunoreactive Renin in Vitreous Fluid From Eyes With and Without Diabetic Retinopathy. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 160-167.	1.8	266